CoronaryAtlas logo
CoronaryAtlas
ASCVD Risk Atlas
← Back to table
C

Chronic heart failure

Comorbid ConditionsDisease / conditionriskpartially modifiable
11
evidence score
PREVENT status

Not a PREVENT input variable.

Causal support

trial evidence

Score components
lit volume: 3meta-analyses: 0trials: 7.8genetic: 0MR bonus:

References (1)

0 meta-analyses / systematic reviews

Clinical trials (5)

NCTTitleStatusTypeInterventions
NCT05737186The Efficacy and Safety of SGLT2 Inhibitors in Improving Heart Failure in Patients With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) and Severe Renal InsufficiencyTERMINATEDINTERVENTIONALSGLT-2 inhibitor
NCT04778787Impact of Sodium-glucose Cotransporter Type 2 Inhibitors on the Course of Cardiorenal Syndrome in Acute Decompensation of Chronic Heart FailureCOMPLETEDINTERVENTIONALStandard list of drugs used for acute decompensation of CHF (loop diuretics, vasodilators, digoxin, inotropic agents, vasopressors), plus dapagliflozin (Forxiga; MP-002596)
NCT03226457Renal and Cardiovascular Effect of Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibition in Combination With Loop Diuretics in Diabetic Patients With Chronic Heart FailureCOMPLETEDINTERVENTIONALEmpagliflozin 25mg, Placebo oral capsule, Frusemide
NCT02653482Dapagliflozin Effect on Symptoms and Biomarkers in Patients With Heart FailureCOMPLETEDINTERVENTIONALDapagliflozin, Dapagliflozin matching placebo
NCT07355088Precision Subtyping and Prognostic Study of Heart Failure Based on Multi-Omics Integration and Clinical Indicators: A Prospective Single-Center Cohort StudyNOT YET RECRUITINGOBSERVATIONAL

Genetic associations (0)

None linked.